Ars Pharma Operations Inc v. Lupin Inc

I. Executive Summary and Procedural Information

• Parties & Counsel:
  • Plaintiff: ARS Pharmaceuticals Operations, Inc. (Delaware) and Aegis Therapeutics, LLC (California)
  • Defendant: Lupin Inc. (Delaware), Lupin Ltd. (India), and Lupin Pharmaceuticals, Inc. (Delaware)
  • Plaintiff's Counsel: McCARTER & ENGLISH, LLP
• Case Identification: 2:26-cv-02036, D.N.J., 02/26/2026
• Venue Allegations: Venue is based on the U.S. presence of Lupin entities in Somerset, New Jersey, which includes what is described as "Lupin's first and only commercial manufacturing facility in the United States."
• Core Dispute: Plaintiffs allege that Defendants' submission of an Abbreviated New Drug Application (ANDA) to the FDA for a generic version of ARS's neffy® (epinephrine nasal spray) constitutes an act of infringement of eight U.S. patents.
• Technical Context: The technology concerns pharmaceutical compositions and methods for the intranasal delivery of epinephrine, primarily for the emergency treatment of severe allergic reactions such as anaphylaxis.
• Key Procedural History: The complaint arises from a Paragraph IV Certification letter sent by Lupin, alleging that the patents-in-suit are invalid and/or will not be infringed by its proposed generic product. The complaint also notes a separate, pending action between the same parties involving the same patents-in-suit in the District of New Jersey, suggesting a pre-existing dispute over this intellectual property.

Case Timeline

II. Technology and Patent(s)-in-Suit Analysis

---

U.S. Patent No. 10,576,156 - "Compositions for drug administration"

• Patent Identification: U.S. Patent No. 10,576,156, entitled "Compositions for drug administration", issued on March 3, 2020 (the '156 Patent). Compl. ¶24

The Invention Explained

• Problem Addressed: The patent's background describes the challenge of administering peptide and protein drugs, which typically have poor oral bioavailability due to hydrolysis in the gastrointestinal tract and poor absorption across mucosal membranes, often requiring administration by injection. '156 Patent, col. 2:1-18
• The Patented Solution: The invention provides pharmaceutical compositions that use an alkylglycoside as a surfactant and absorption enhancer. This component is described as stabilizing the therapeutic agent and increasing its absorption through mucosal membranes, such as those in the nasal cavity, without causing significant irritation or toxicity. '156 Patent, abstract '156 Patent, col. 1:31-39
• Technical Importance: This technology offers a means for non-invasive delivery of macromolecules, potentially achieving bioavailabilities comparable to injection and expanding the clinical utility of peptide and protein-based therapeutics. '156 Patent, col. 2:63-col. 3:5

Key Claims at a Glance

The complaint alleges infringement of one or more claims without specifying which ones Compl. ¶47 Independent claim 1 is representative of the patent's core composition claims:

• An intranasal pharmaceutical composition comprising:
  • epinephrine; and
  • between about 0.05% and 0.5% (w/v) of an alkylglycoside;
  • wherein the alkylglycoside is dodecyl-beta-D-maltoside,
  • wherein the composition is an aqueous solution formulated for intranasal delivery to a subject, and provides systemic absorption of epinephrine upon delivery to the subject, and
  • wherein the composition has a pH of about 2.0 to 5.0.

---

U.S. Patent No. 10,682,414 - "Intranasal epinephrine formulations and methods for the treatment of disease"

• Patent Identification: U.S. Patent No. 10,682,414, entitled "Intranasal epinephrine formulations and methods for the treatment of disease", issued on June 16, 2020 (the '414 Patent). Compl. ¶25

The Invention Explained

• Problem Addressed: The patent background discusses the need for a needle-free, non-invasive, and reliable method for administering epinephrine in emergency situations like anaphylaxis, citing the high variability, product quality problems, and patient reluctance associated with auto-injectors. '414 Patent, col. 2:1-33
• The Patented Solution: The invention is a method for treating type-1 hypersensitivity reactions by administering a specific dose of epinephrine (between 0.40 mg and 2.4 mg) in a single-dose nasal spray formulation. This approach is intended to provide a more convenient, rapid, and reliable means of dosing compared to intramuscular injections. '414 Patent, abstract '414 Patent, col. 2:45-55
• Technical Importance: This method provides a discrete, needle-free alternative to auto-injectors that can be administered by an untrained individual, potentially improving patient compliance and outcomes in emergency allergic reactions. '414 Patent, col. 2:38-44

Key Claims at a Glance

The complaint does not specify which claims are asserted Compl. ¶53 Independent claim 1 is representative of the patent's core method claims:

• A method of treating a type-1 hypersensitivity reaction in a human comprising an intranasal administration of a nasal spray pharmaceutical formulation to the human with the type-1 hypersensitivity reaction, wherein a single intranasally administered dose of the nasal spray pharmaceutical formulation comprises:
  • a) between 0.1 mg and about 2.4 mg of epinephrine, or a salt thereof, wherein epinephrine, or a salt thereof, is the only pharmaceutically active ingredient in the pharmaceutical formulation;
  • b) one or more other agents as excipients selected from the group consisting of absorption enhancement agents, isotonicity agents, stabilizing agents, antioxidants, preservatives, and pH adjustment agents; and
  • c) water;
  • wherein the nasal spray pharmaceutical formulation has a pH between about 3.0 and about 5.0; and wherein the volume of the single intranasally administered dose of the nasal spray pharmaceutical formulation is between 25 µL and about 250 µL.

---

Multi-Patent Capsule Analysis

• U.S. Patent No. 11,173,209

  • Patent Identification: U.S. Patent No. 11,173,209, "Compositions for drug administration", issued November 16, 2021 (the '209 Patent). Compl. ¶26
  • Technology Synopsis: The patent relates to pharmaceutical compositions containing an alkylglycoside as a drug administration and absorption-enhancing agent, similar to the '156 Patent. The technology aims to improve the bioavailability of therapeutic agents delivered across mucosal membranes.
  • Asserted Claims: The complaint does not specify claims. Compl. ¶60
  • Accused Features: The Lupin ANDA Product is accused of infringement based on its filing with the FDA. Compl. ¶60

• U.S. Patent No. 11,191,838

  • Patent Identification: U.S. Patent No. 11,191,838, "Intranasal epinephrine formulations and methods for the treatment of disease", issued December 7, 2021 (the '11-838 Patent). Compl. ¶27
  • Technology Synopsis: The patent relates to specific intranasal epinephrine formulations and methods for treating disease, similar to the '414 Patent. The invention is directed at providing a needle-free emergency treatment for conditions like anaphylaxis.
  • Asserted Claims: The complaint does not specify claims. Compl. ¶67
  • Accused Features: The Lupin ANDA Product is accused of infringement based on its filing with the FDA. Compl. ¶67

• U.S. Patent No. 11,717,571

  • Patent Identification: U.S. Patent No. 11,717,571, "Intranasal epinephrine formulations and methods for the treatment of disease", issued August 8, 2023 (the '571 Patent). Compl. ¶28
  • Technology Synopsis: The patent relates to specific intranasal epinephrine formulations and methods for treating disease, similar to the '414 Patent. The invention is directed at providing a needle-free emergency treatment for conditions like anaphylaxis.
  • Asserted Claims: The complaint does not specify claims. Compl. ¶74
  • Accused Features: The Lupin ANDA Product is accused of infringement based on its filing with the FDA. Compl. ¶74

• U.S. Patent No. 11,744,895

  • Patent Identification: U.S. Patent No. 11,744,895, "Intranasal epinephrine formulations and methods for the treatment of disease", issued September 5, 2023 (the '895 Patent). Compl. ¶29
  • Technology Synopsis: The patent relates to specific intranasal epinephrine formulations and methods for treating disease, similar to the '414 Patent. The invention is directed at providing a needle-free emergency treatment for conditions like anaphylaxis.
  • Asserted Claims: The complaint does not specify claims. Compl. ¶81
  • Accused Features: The Lupin ANDA Product is accused of infringement based on its filing with the FDA. Compl. ¶81

• U.S. Patent No. 11,918,655

  • Patent Identification: U.S. Patent No. 11,918,655, "Intranasal epinephrine formulations and methods for the treatment of disease", issued March 5, 2024 (the '655 Patent). Compl. ¶30
  • Technology Synopsis: The patent relates to specific intranasal epinephrine formulations and methods for treating disease, similar to the '414 Patent. The invention is directed at providing a needle-free emergency treatment for conditions like anaphylaxis.
  • Asserted Claims: The complaint does not specify claims. Compl. ¶88
  • Accused Features: The Lupin ANDA Product is accused of infringement based on its filing with the FDA. Compl. ¶88

• U.S. Patent No. 12,324,838

  • Patent Identification: U.S. Patent No. 12,324,838, "Intranasal epinephrine formulations and methods for the treatment of disease", issued June 10, 2025 (the '12-838 Patent). Compl. ¶31
  • Technology Synopsis: The patent relates to specific intranasal epinephrine formulations and methods for treating disease, similar to the '414 Patent. The invention is directed at providing a needle-free emergency treatment for conditions like anaphylaxis.
  • Asserted Claims: The complaint does not specify claims. Compl. ¶95
  • Accused Features: The Lupin ANDA Product is accused of infringement based on its filing with the FDA. Compl. ¶95

III. The Accused Instrumentality

• Product Identification: The accused instrumentality is Defendants' proposed generic drug product described in ANDA No. 221269 ("the Lupin ANDA Product") Compl. ¶1 Compl. ¶17
• Functionality and Market Context: The Lupin ANDA Product is identified as a 1 mg/spray epinephrine nasal spray intended for the emergency treatment of type I allergic reactions Compl. ¶1 Compl. ¶37 The complaint alleges that by filing its ANDA, Lupin has represented to the FDA that its product is bioequivalent to ARS's neffy® drug product Compl. ¶39 As a generic product submitted through the ANDA pathway, it is positioned to compete with the branded neffy® product upon receiving FDA approval Compl. ¶46

IV. Analysis of Infringement Allegations

The complaint does not provide a detailed infringement analysis or claim chart. The act of infringement alleged is the statutory act of submitting an ANDA under 35 U.S.C. § 271(e)(2)(A) for a drug product claimed in a patent or the use of which is claimed in a patent Compl. ¶44 The infringement theory is that the commercial manufacture, use, or sale of the Lupin ANDA Product would infringe the patents-in-suit Compl. ¶42

No probative visual evidence provided in complaint.

---

10,576,156 Patent Infringement Allegations

---

10,682,414 Patent Infringement Allegations

---

• Identified Points of Contention:
  • Scope Questions: For the '156 Patent, a central question may be whether Lupin's formulation contains the specific excipient "dodecyl-beta-D-maltoside" within the claimed concentration range. Lupin may have designed its product with a different, non-infringing excipient that it will argue is not an "alkylglycoside" as that term is understood in the patent.
  • Technical Questions: Since this is an ANDA litigation, the infringement analysis is a hypothetical one based on the product described in the ANDA. The primary technical dispute will be a comparison of the proposed generic product's composition and proposed labeling instructions against the asserted patent claims. Lupin's Paragraph IV letter asserts non-infringement and invalidity, suggesting it will argue both that its product does not meet the claim limitations and that the claims are invalid over prior art Compl. ¶42

V. Key Claim Terms for Construction

• The Term: "alkylglycoside" (from '156 Patent, claim 1)

  • Context and Importance: The definition of this term is critical because infringement of the composition claims may depend on whether the specific absorption enhancer used in Lupin's ANDA product falls within the scope of this term. Practitioners may focus on this term to determine if Lupin's formulation, which may use a different surfactant, still reads on the claims.
  • Intrinsic Evidence for Interpretation:
    • Evidence for a Broader Interpretation: The specification provides a broad definition, stating an "alkylglycoside" refers to "any sugar joined by a linkage to any hydrophobic alkyl" and lists numerous examples beyond maltosides, such as glucosides and sucrosides with varying alkyl chain lengths '156 Patent, col. 25:59-col. 26:12
    • Evidence for a Narrower Interpretation: While the specification is broad, claim 1 specifically recites that the alkylglycoside is "dodecyl-beta-D-maltoside." A defendant may argue that this specific language in the claim body limits the broader term for the purposes of that claim, or that the patentee disclaimed broader scope during prosecution.

• The Term: "a single intranasally administered dose" (from '414 Patent, claim 1)

  • Context and Importance: This term relates to the method of administration. The dispute may turn on what constitutes a "single dose," for example, whether it is a single spray, multiple sprays within a short time, or the entire content of a single-use device. The construction will be important for assessing both infringement and potential invalidity arguments based on prior art administration methods.
  • Intrinsic Evidence for Interpretation:
    • Evidence for a Broader Interpretation: The plain meaning suggests one administration event. The claim language itself does not further limit the term to a specific number of actuations or volume, beyond specifying the total amount of epinephrine.
    • Evidence for a Narrower Interpretation: The specification describes administration via a "small compact unit dose sprayer device" '414 Patent, col. 2:42-44, and other claims specify delivery in "a single dose of the nasal spray pharmaceutical formulation" (e.g., '414 Patent, claim 1). A party might argue that these disclosures limit the "single dose" to what can be delivered in a single actuation from such a device.

VI. Other Allegations

• Indirect Infringement: The complaint alleges that Lupin's manufacture, use, and sale of its proposed ANDA product will induce infringement of the patents-in-suit Compl. ¶49 Compl. ¶55 The factual basis for this allegation is the statutory framework of ANDA litigation, where the proposed drug label, which will presumably instruct users to perform the patented methods, serves as evidence of intent to induce.
• Willful Infringement: The complaint does not explicitly allege willful infringement.

VII. Analyst's Conclusion: Key Questions for the Case

• A central issue will be one of chemical scope: Does Lupin's proposed generic formulation contain the precise excipients, such as "dodecyl-beta-D-maltoside," required by the composition claims of patents like the '156 Patent? The case may turn on whether Lupin has successfully designed around the asserted composition claims with alternative, non-infringing formulation components.
• A second key question will be one of invalidity: Lupin's Paragraph IV certification asserts that the patents-in-suit are invalid Compl. ¶42 A core element of the case will therefore be Lupin's challenge to the validity of the asserted claims based on prior art or other legal grounds, such as lack of enablement or written description for the claimed formulations and methods.
• Finally, a key legal question in this ANDA context is one of statutory infringement: For the asserted method claims, will the instructions for use on the proposed label for Lupin's ANDA Product direct users to perform the steps of the patented methods, thereby establishing future induced infringement under 35 U.S.C. § 271(e)(2)(A)?